Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Groundbreaking Artificial Heart Implanted At UMDNJ-Robert Wood Johnson Medical School And Robert Wood Johnson University Hospital
Robert Wood Johnson University Hospital and UMDNJ-Robert Wood Johnson Medical School jointly announce the successful implant of the AbioCor® Total Replacement Heart, the world"s first completely self-contained, fully implantable artificial heart, as well as the first internal artificial organ. The surgery was led by Mark Anderson, MD, associate professor of surgery at UMDNJ-Robert Wood Johnson Medical School and chief of the section of cardiac surgery at both the medical school and Robert Wood Johnson University Hospital, and assisted by Juan Plate, MD, assistant professor of surgery at UMDNJ-Robert Wood Johnson Medical School and an attending surgeon at Robert Wood Johnson University Hospital. Robert Wood Johnson University Hospital is one of only three centers nationwide approved to perform the surgery and the only one in the New York and Philadelphia areas. Dr. Anderson is one of a handful of physicians nationwide trained to perform this procedure. This is the first time the AbioCor has been implanted in a patient since the completion of clinical trials and approval by the Food and Drug Administration.

Hospital Doctors Must Learn About Money To Drive Better Treatment And NHS Efficiency, UK
Hospital doctors must learn the basics of NHS finance to help drive greater efficiency and better outcomes for patients, according to the Academy of Medical Royal Colleges and the Audit Commission.
News of the day
Healthier, Longer-Lasting Fish Filets With Edible Coating
Consumers may be able to eat longer-lasting, potentially healthier fish fillets if research at Oregon State University makes its way to the supermarket.
Oncology

PanGenetics Receives Approval For Clinical Evaluation Of Anti-NGF Antibody In Patients With Chronic Pain

PanGenetics B.V. announced that the Competent Authority of the Netherlands has approved the Clinical Trials Application for a first-in-man study with antibody PG110. This humanized antibody is a member of the class of Nerve Growth Factor (NGF) inhibitors which represent a promising novel approach in the treatment of chronic pain. PG110 will be evaluated in patients suffering from pain caused by osteoarthritis (OA). The clinical trial is designed as a double blind, placebo controlled study and will be conducted in a single site in Utrecht, the Netherlands, in collaboration with Kendle International. The primary objective of the Phase I study is to evaluate the safety and tolerability of single ascending doses of PG110. In addition, the dosing in patients will allow the evaluation of pharmacodynamic and clinical parameters which will provide further insight into the activity of PG110. The results of the study, which includes an extended follow-up period, are expected in the second half of 2010. Kevin Johnson, CEO of PanGenetics, commented: "The class of NGF-inhibitors is the first real break-through in pain therapy for decades. Preclinical studies of PG110 demonstrated that it is a very potent and differentiated product in this class. We are looking forward to starting clinical studies of PG110. This will be our second clinical program initiation in the last 12 months and our anti-CD40 antibody PG102 is progressing well in a phase 1 study in psoriatic arthritis patients." About PG110 PG110 is a humanised antibody that binds to Nerve Growth Factor (NGF) with high affinity. NGF is the prototypical member of the family of neurotrophin growth factors, which are involved in the growth and survival of nervous tissue. PG110 prevents the interaction of NGF with both its receptors, the high-affinity receptor TrKA and the low affinity receptor p75. This interaction plays a key role in pain transduction mechanisms in the adult peripheral nervous system. PG110 does not cross-react with other neurotrophins and therefore is a highly specific function-blocking molecule that is able to neutralise NGF bioactivity, both in vitro and in vivo. The precursor to PG110 originated in Lay Line Genomics and after the program was acquired by PanGenetics a comprehensive CMC and preclinical development program was initiated. PanGenetics B.V.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009